Short Interest in CAN-FITE BIOPHA/S (CANF) Rises By 11.7%

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 356,891 shares, an increase of 11.7% from the October 15th total of 319,636 shares. Based on an average daily trading volume, of 63,322 shares, the days-to-cover ratio is currently 5.6 days.

Separately, HC Wainwright set a $8.00 price target on CAN-FITE BIOPHA/S and gave the stock a “buy” rating in a research note on Monday, August 6th.

CAN-FITE BIOPHA/S stock opened at $1.33 on Friday. CAN-FITE BIOPHA/S has a 12 month low of $1.12 and a 12 month high of $2.75.

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) last released its quarterly earnings results on Friday, August 31st. The biotechnology company reported ($0.06) EPS for the quarter. The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $2.00 million.

TRADEMARK VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at

CAN-FITE BIOPHA/S Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with's FREE daily email newsletter.

Leave a Reply